Safety of High-Dose Corticosteroids for the Treatment of Autoimmune Inner Ear Disease
Authors:
- Thomas H. AlexanderTAThomas H. Alexander
- Michael H. WeismanMWMichael H. Weisman
- Jennifer M. DereberyJDJennifer M. Derebery
- Mark A. EspelandMEMark A. Espeland
- Bruce J. GantzBGBruce J. Gantz
- A. Julianna GulyaAGA. Julianna Gulya
- Paul E. HammerschlagPHPaul E. Hammerschlag
- Maureen HannleyMHMaureen Hannley
- Gordon B. HughesGHGordon B. Hughes
- Richard MoscickiRMRichard Moscicki
- Ralph A. NelsonRNRalph A. Nelson
- John K. NiparkoJNJohn K. Niparko
- 1 June 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 30 (4) , 443-448
Abstract
To report the adverse effects associated with prolonged high-dose prednisone for the treatment of autoimmune inner ear disease (AIED). Prospective data collected as part of a multicenter, randomized, controlled trial for the treatment of corticosteroid-responsive AIED with methotrexate. Tertiary referral centers. One hundred sixteen patients with rapidly progressive, bilateral sensorineural hearing loss. All patients completed a 1-month course of prednisone (60 mg/d). In Phase 2, 67 patients with improvement in hearing underwent a monitored 18-week prednisone taper, resulting in 22 weeks of prednisone therapy at an average dose of 30 mg per day. Thirty-three patients were randomized to receive methotrexate in Phase 2. Thirty-four patients received prednisone and placebo. Adverse events (AE) in patients treated with prednisone only. Of 116 patients, 7 had to stop prednisone therapy during the 1-month challenge phase due to AE. Of 34 patients, 5 were unable to complete the full 22-week course of prednisone due to AE. The most common AE was hyperglycemia, which occurred in 17.6% of patients participating in Phase 2. Weight gain was also common, with a mean increase in body mass index of 1.6 kg/m2 (95% confidence interval, 0.77-2.3) during the 22-week steroid course. Patients entering Phase 2 were followed for a mean of 66 weeks. No fractures or osteonecrosis were reported. Although high-dose corticosteroids are associated with known serious side effects, prospective data in the literature are limited. The present study suggests that with appropriate patient selection, monitoring, and patient education, high-dose corticosteroids are a safe and effective treatment of AIED.Keywords
This publication has 31 references indexed in Scilit:
- Local Perfusion of the Tumor Necrosis Factor α Blocker Infliximab to the Inner Ear Improves Autoimmune Neurosensory Hearing LossAudiology and Neurotology, 2006
- Etanercept Treatment for Autoimmune Inner Ear Disease: Results of a Pilot Placebo-Controlled StudyOtology & Neurotology, 2005
- Immune-mediated inner ear disease: 10-year experienceSeminars in Arthritis and Rheumatism, 2004
- Treatment of Corticosteroid-Responsive Autoimmune Inner Ear Disease With MethotrexateJAMA, 2003
- Open trial of methotrexate as treatment for autoimmune hearing lossArthritis & Rheumatism, 2001
- Methotrexate management of immunemediated cochleovestibular disordersOtolaryngology–Head and Neck Surgery, 1997
- Fundamental immune mechanisms of the brain and inner earOtolaryngology–Head and Neck Surgery, 1995
- Azathioprine in Combination with Steroids in the Treatment of Autoimmune Inner-Ear DiseaseJournal of International Medical Research, 1993
- Theoretical and practical implications for plasmapheresis in autoimmune inner ear diseaseThe Laryngoscope, 1989
- Autoimmune Sensorineural Hearing LossAnnals of Otology, Rhinology & Laryngology, 1979